GlassScriptPhysician profile
Tarun Popli
NPI 1376776443
$1,255.48
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $574 · 2020: $395 · 2021: $99.00 · 2022: $138 · 2024: $49.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $49.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $49.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Products, LP | $278.98 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $126.56 | 2019 | |
| Insmed, INC. | $125.00 | 2020 | |
| Janssen Pharmaceuticals, INC | $120.66 | 2019-2022 | |
| Gilead Sciences, INC. | $119.03 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $112.89 | 2019-2022 | |
| Janssen Biotech, INC. | $96.17 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $69.26 | 2019 | |
| Pfizer INC. | $66.47 | 2019 | |
| Silk Road Medical, INC. | $49.18 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Astrazeneca Pharmaceuticals LP | $49.15 | 2019 | |
| Cvrx, INC. | $28.82 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tarun Popli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.